Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -1-
February 19, 2001
- Nat'l Univ Hospitals Directors Council to Propose One Record per Patient
February 19, 2001
- Hitachi Medical Transfers Nursing Care Business to Group Company
February 19, 2001
- BUSINESS NEWS IN BRIEF -2-
February 19, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 19, 2001
- Boston Scientific Ties Up with Islaeri, Canadian Firms in Cardiac Electrophysiology
February 19, 2001
- PMSB to Draft Criteria for Disclosure of Information
February 19, 2001
- Takara Shuzo Ties Up with GenCom for Genomic Analysis of ES Cells
February 19, 2001
- Mitsubishi Chemical Licenses SPR Technology from Quantech
February 19, 2001
- Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
- Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
- Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
- Society to Request 3-month Prescription Periods for Anti-HIV Drugs
February 19, 2001
- Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
- RA Patient Group Holds Survey on Clinical Trials
February 19, 2001
- Long, Short-term Goals Must Be Set for Reform: JMA President
February 19, 2001
- Asthma Telemedicine Should Reduce Asthma Deaths: Teijin Seminar
February 19, 2001
- Chugai's '75-year History' Published
February 19, 2001
- Standard Drug Name, Lab Test Masters Completed
February 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…